№ lp_2_3_47643
File format: docx Character count: 35043 File size: 88 KB
Version: NENC v1.0
Date published: 12th December 2024
Changes since previous version: Adapted from RDTC v1.2 published 26th November 2024
Planned review date: March 2026
Licensed and agreed off-label indications: Azathioprine, Mercaptopurine
Specialist: NHS healthcare professionals
Target audience: Healthcare professionals in adult services
Indication: Auto-immune chronic active hepatitis, Behçet’s disease, inflammatory bowel disease, and others
Type of document: Shared Care Protocol
Clinical guidelines: BNF, NICE, BSR, BHPR
Local variations: Gateshead
Period of use: Ongoing, review by March 2026
Background: Azathioprine and mercaptopurine as disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of chronic inflammatory conditions.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Mycophenolate mofetil and mycophenolic acid for patients within adult services (non-transplant indications)
Version: HNY v2.0
Replaces version: HNY v1.0
Clinical content last reviewed: November 2023
Next review date: April 2028
Note: RDTC v1.0 8th March 2024
Local review and adoption: September 2025
Approved for use by HNY ICB: 1st October 2025
Clinical content reviewed and updated by RDTC: November 2023
Azathioprine and mercaptopurine for patients within adult services
Version: HNY v2.0
Replaces version: HNY v1.0
Clinical content last reviewed: October 2023
Next review date: September 2028
Date published: 1st October 2025
Approved for use by Humber and North Yorkshire ICB: 1st October 2025
Local content added: September 2025
Note: Licensed indications updated to reflect currently available products
Background: Azathioprine and mercaptopurine are disease modifying anti-rheumatic drugs (DMARDs). They are used as immunosuppressant anti-metabolites either alone or in combination with other agents (usually corticosteroids).
Type: Shared Care Protocol
Region / city: Humber and North Yorkshire
Organization / institution: Humber and North Yorkshire ICB
Author: RDTC
Target audience: NHS healthcare professionals
Period of validity: Until September 2028
Approval date: 1st October 2025
Date of last review: October 2023
Date of next review: September 2028
Azathioprine and mercaptopurine for patients within adult services
Version: HNY v2.0
Replaces version: HNY v1.0
Clinical content last reviewed: October 2023
Next review date: September 2028
Date published: 1st October 2025
Approved for use by Humber and North Yorkshire ICB: 1st October 2025
Local content added: September 2025
Note: Licensed indications updated to reflect currently available products
Background: Azathioprine and mercaptopurine are disease modifying anti-rheumatic drugs (DMARDs). They are used as immunosuppressant anti-metabolites either alone or in combination with other agents (usually corticosteroids).
Type: Shared Care Protocol
Region / city: Humber and North Yorkshire
Organization / institution: Humber and North Yorkshire ICB
Author: RDTC
Target audience: NHS healthcare professionals
Period of validity: Until September 2028
Approval date: 1st October 2025
Date of last review: October 2023
Date of next review: September 2028
Topics: non-transplant Azathioprine mercaptopurine